Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shenglan Zou"'
Publikováno v:
Journal of Cardiothoracic Surgery, Vol 19, Iss 1, Pp 1-7 (2024)
Abstract Objective The purpose of this study was to investigate the diagnostic value of circ_0013958 in acute myocardial infarction (AMI) patients and its influence on the prognosis of AMI patients. Methods The GSE160717 dataset was downloaded from t
Externí odkaz:
https://doaj.org/article/a0e33c0645b7479eac4cdc644403aae0
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
BackgroundIschemic heart disease (IHD) is a major global health concern, and its burden among young adults aged 25–49 years remains underexplored. This study aims to provide a comprehensive assessment of the global burden and trends of IHD over the
Externí odkaz:
https://doaj.org/article/84af4ff98ab74a10bc26ec7663d9ac44
Autor:
Lina Jia, Yi Fang, Shenglan Zou, Mengyue Zhao, Yuhong Sun, Jian Han, Jingyu Yang, Yong Ren, Mei Han, Qixiang Hua, Xuefei Bao, Guoliang Chen, Chunfu Wu, Hong Li, Lihui Wang
Publikováno v:
Cell Death and Disease, Vol 10, Iss 6, Pp 1-13 (2019)
Cell Death & Disease
Cell Death & Disease
Cisplatin yields significant efficacy and is generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, acquired resistance strongly limits its application. Here, we identified that a novel histone deacetylase (HDAC) inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7f05f60e82e38dc3db6778e7ffdd076
http://link.springer.com/article/10.1038/s41419-019-1597-y
http://link.springer.com/article/10.1038/s41419-019-1597-y
Autor:
Jingyu Yang, Xuefei Bao, Jiayu Zhang, Guoliang Chen, Chunfu Wu, Changshun Bao, Shenglan Zou, Lihui Wang, Yuhong Sun
Publikováno v:
Bioorganic Chemistry. 86:696-704
A series of novel N-hydroxypropenamides containing adamantane moiety were identified and most of them exhibited HDAC inhibitory activity and could reverse the resistance of cisplatin in NSCLC cell lines. In this process, molecular docking was employe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc98af30092e7ec6481fcf18497a1b7d
https://doi.org/10.1016/j.bioorg.2019.02.047
https://doi.org/10.1016/j.bioorg.2019.02.047
Autor:
Shenglan Zou, Xiangzhong Yuan, Fang Wuhong, Lihui Wang, Xiaorui Jiang, Meng Li, Lina Jia, Jingyu Yang, Chunfu Wu, Guoliang Chen, Xinwei Liu, Yong Ren, Huahuan Li
Publikováno v:
Cell Death & Disease
Chemotherapy paclitaxel yields significant reductions in tumor burden in the majority of advanced non-small cell lung cancer (NSCLC) patients. However, acquired resistance limits its clinical use. Here we demonstrated that the histone deacetylase (HD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be884a3e028fe781b0703e66da8d8e92
https://pubmed.ncbi.nlm.nih.gov/26794658
https://pubmed.ncbi.nlm.nih.gov/26794658